ERA-923 in Treating Postmenopausal Women With Metastatic Breast Cancer

Phase 2 Unknown H. Lee Moffitt Cancer Center and Research Institute National Cancer Institute (NCI) · collab

Treatment

Summary

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ERA-923 may fight breast cancer by blocking the uptake of estrogen by the tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of ERA-923 in treating postmenopausal women who have metastatic breast cancer that no longer responds to tamoxifen.

Timeline

Start: 2000-06
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PIPENDOXIFENE	Small molecule	—	Oral

ERA-923 in Treating Postmenopausal Women With Metastatic Breast Cancer

Summary

Timeline

Drugs

Indications